When.com Web Search

  1. Ads

    related to: camp4 therapeutics corp ipo schedule today

Search results

  1. Results From The WOW.Com Content Network
  2. Initial public offering - Wikipedia

    en.wikipedia.org/wiki/Initial_public_offering

    An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors [1] and usually also to retail (individual) investors. [2] An IPO is typically underwritten by one or more investment banks, who also arrange for the shares to be listed on one or more stock exchanges.

  3. Why Summit Therapeutics Rocketed Over 60% Today - AOL

    www.aol.com/why-summit-therapeutics-rocketed...

    Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed as high as 75.2% Monday, before settling into a 57.5% gain as of 1:27 PM EDT.. The biotech firm released the results of a Phase III study on ...

  4. J&J-backed Rapport Therapeutics seeks about $637 million ...

    www.aol.com/news/j-j-backed-rapport-therapeutics...

    The U.S. IPO market is staging a strong comeback after two dismal years, thanks to a rally in the stock market and growing optimism of a possible interest rate cut this year. Rapport, backed by ...

  5. 7 upcoming IPOs to watch in 2024 - AOL

    www.aol.com/finance/7-upcoming-ipos-watch-2024...

    Some 108 companies conducted their IPO in 2023 and raised $19.4 billion, according to Renaissance Capital. Those figures rose markedly from the 2022 doldrums of 71 IPOs and just $7.7 billion raised.

  6. Kite Pharma - Wikipedia

    en.wikipedia.org/wiki/Kite_Pharma

    In May 2014, Kite Pharma filed a registration with the SEC for an initial public offering (IPO) of its common stock. [45] In June 2014, Kite Pharma sold 8,625,000 shares of its common stock in their IPO at $17.00 per share, for gross proceeds of $146.6 million. [46] [47] [48] The company listed on the NASDAQ Global market under the symbol ...

  7. Juno Therapeutics - Wikipedia

    en.wikipedia.org/wiki/Juno_Therapeutics

    The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. [2] In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene. [3]